Recurrent Glioblastoma
Showing 1 - 25 of 97
Recurrent Glioblastoma Trial in Brussels (Neo-adjuvant nivolumab and ipililumab IV + adjuvant nivolumab and ipililumab IV,
Not yet recruiting
- Recurrent Glioblastoma
- Neo-adjuvant nivolumab and ipililumab IV + adjuvant nivolumab and ipililumab IV
- +2 more
-
Brussels, BelgiumUZ Brussel
Oct 23, 2023
Glioblastoma, Recurrent Glioblastoma, Resectable Glioblastoma Trial in Los Angeles (Biospecimen Collection, Magnetic Resonance
Recruiting
- Glioblastoma
- +2 more
- Biospecimen Collection
- +2 more
-
Los Angeles, CaliforniaUCLA / Jonsson Comprehensive Cancer Center
Oct 13, 2023
Brain Cancer, Glioblastoma, Metastatic Cancer Trial in New York (Trastuzumab deruxtecan)
Recruiting
- Brain Cancer
- +4 more
- Trastuzumab deruxtecan
-
New York, New YorkMemorial Sloan Kettering Cancer Center (All Protocol Activities)
Sep 22, 2023
Recurrent Glioblastoma, Glioblastoma Multiforme, GBM Trial in Charlottesville (5-ALA and Low-Intensity Focused Ultrasound (SDT))
Not yet recruiting
- Recurrent Glioblastoma
- +2 more
- 5-ALA and Low-Intensity Focused Ultrasound (SDT)
-
Charlottesville, VirginiaUniversity of Virginia
Sep 10, 2023
Glioblastoma Multiforme, Adult, Recurrent Glioblastoma Trial in Rotterdam (Pitavastatin calcium)
Not yet recruiting
- Glioblastoma Multiforme, Adult
- Recurrent Glioblastoma
- Pitavastatin calcium
-
Rotterdam, NetherlandsErasmus MC
Aug 3, 2023
Recurrent Glioblastoma Trial in Portland (TVI-Brain 1)
Available
- Recurrent Glioblastoma
- TVI-Brain 1
-
Portland, OregonProvidence St. Vincent Medical Center
Jun 28, 2023
Glioblastoma, Recurrent Glioblastoma, GBM Trial in Worldwide (SonoCloud-9 (SC9), Carboplatin, Lomustine)
Not yet recruiting
- Glioblastoma
- +2 more
- SonoCloud-9 (SC9)
- +3 more
-
Chicago, Illinois
- +7 more
Jun 5, 2023
Recurrent Glioblastoma Trial in Houston (Pembrolizumab, Exablate MRgFUS + neoadjuvant pembolizumab)
Not yet recruiting
- Recurrent Glioblastoma
- Pembrolizumab
- Exablate MRgFUS + neoadjuvant pembolizumab
-
Houston, TexasM D Anderson Cancer Center
May 18, 2023
Recurrent Glioblastoma Trial (Targeted Epidermal Growth Factor Receptor Variant III(EGFRvIII) autochimeric antigen receptor T
Not yet recruiting
- Recurrent Glioblastoma
- Targeted Epidermal Growth Factor Receptor Variant III(EGFRvIII) autochimeric antigen receptor T cell injection
- (no location specified)
Apr 4, 2023
Glioblastoma, Recurrent Glioblastoma Trial in Atlanta (Avutometinib, Biospecimen Collection, Defactinib)
Not yet recruiting
- Glioblastoma
- Recurrent Glioblastoma
- Avutometinib
- +2 more
-
Atlanta, GeorgiaEmory University Hospital/Winship Cancer Institute
Mar 22, 2023
Recurrent Glioblastoma Trial in Jacksonville (Allogeneic Adipose-derived Mesenchymal Stem Cells, Biospecimen Collection,
Not yet recruiting
- Recurrent Glioblastoma
- Allogeneic Adipose-derived Mesenchymal Stem Cells
- +4 more
-
Jacksonville, FloridaMayo Clinic in Florida
Mar 16, 2023
Recurrent High-grade Glioma, Recurrent Glioblastoma, Recurrent Anaplastic Astrocytoma Trial in Incheon (500mg/kg/3hr followed by
Recruiting
- Recurrent High-grade Glioma
- +3 more
- 500mg/kg/3hr followed by neutron irradiation to reach maximum brain dose of 9Gy-Eq
- +2 more
-
Incheon, Korea, Republic ofGachon University Gil Medical Center
Feb 19, 2023
Recurrent Glioblastoma Trial (fractionated radiotherapy, cadonilimab)
Not yet recruiting
- Recurrent Glioblastoma
- fractionated radiotherapy
- cadonilimab
- (no location specified)
Feb 20, 2023
Diffuse Astrocytoma, IDH-Wildtype, Recurrent Glioblastoma Trial in United States (biological, procedure, radiation)
Suspended
- Diffuse Astrocytoma, IDH-Wildtype
- Recurrent Glioblastoma
- Atezolizumab
- +5 more
-
Los Angeles, California
- +73 more
Jan 31, 2023
Glioblastoma, Recurrent Glioblastoma Trial in United States (ASP8374, cemiplimab)
Active, not recruiting
- Glioblastoma
- Recurrent Glioblastoma
-
Boston, Massachusetts
- +3 more
Jan 13, 2023
Recurrent Glioblastoma, Recurrent Gliosarcoma Trial in Houston (other, biological, procedure)
Active, not recruiting
- Recurrent Glioblastoma
- Recurrent Gliosarcoma
- Laboratory Biomarker Analysis
- +3 more
-
Houston, TexasM D Anderson Cancer Center
Dec 19, 2022
Giant Cell Glioblastoma, Recurrent Glioblastoma, Recurrent Gliosarcoma Trial in Rochester (Laboratory Biomarker Analysis,
Active, not recruiting
- Giant Cell Glioblastoma
- +2 more
- Laboratory Biomarker Analysis
- Malignant Glioma Tumor Lysate-Pulsed Autologous Dendritic Cell Vaccine
-
Rochester, MinnesotaMayo Clinic
Jan 4, 2023
Recurrent Glioblastoma, Refractory Glioblastoma Trial in Hangzhou, Huzhou, Ningbo (Temozolomide, B7-H3 CAR-T)
Recruiting
- Recurrent Glioblastoma
- Refractory Glioblastoma
- Temozolomide
- B7-H3 CAR-T
-
Hangzhou, Zhejiang, China
- +2 more
Dec 25, 2022
Recurrent Glioblastoma Trial (Niraparib, Re-irradiation (re-RT))
Not yet recruiting
- Recurrent Glioblastoma
- Niraparib
- Re-irradiation (re-RT)
- (no location specified)
Dec 23, 2022
Recurrent Glioblastoma Trial in Beijing (Laser interstitial thermal therapy, Temozolomide)
Active, not recruiting
- Recurrent Glioblastoma
- Laser interstitial thermal therapy
- Temozolomide
-
Beijing, ChinaBeijing Tiantan Hospital
Dec 22, 2022
Glioblastoma, Malignant Glioma, Recurrent Glioblastoma Trial in Boston (CARv3-TEAM-E T cells)
Not yet recruiting
- Glioblastoma
- +3 more
- CARv3-TEAM-E T cells
-
Boston, MassachusettsMassachusetts General Hospital Cancer Center
Dec 13, 2022
Recurrent Glioblastoma Trial (Sintilimab plus Bevacizumab and Temozolomide)
Not yet recruiting
- Recurrent Glioblastoma
- Sintilimab plus Bevacizumab and Temozolomide
- (no location specified)
Nov 27, 2022
Glioblastoma, Recurrent Glioblastoma Trial in San Francisco (RMC-5552)
Not yet recruiting
- Glioblastoma
- Recurrent Glioblastoma
-
San Francisco, CaliforniaUniversity of California, San Francisco
Nov 28, 2022